How Long Can You Live With AML Without Treatment?

Median survival for people with acute myeloid leukemia who receive no treatment is roughly two months, according to multiple population-based analyses.¹ That figure reflects the typical case, but there is real variation behind it. A small fraction of untreated patients survive a year or longer, and an even smaller group lives well beyond what anyone would predict. What drives that spread, and what actually happens in the body when AML goes unchecked, matters for anyone facing or helping someone weigh difficult treatment decisions.

Where the Two-Month Figure Comes From

AML is one of the fastest-moving cancers. A large population-based study of older patients found that those who received no treatment had a median survival of two months, compared with six months for those who were treated.¹ A separate registry-based analysis put the untreated figure at approximately two months as well, while noting that with treatment, about 45 percent of patients survive five years or more.² These are medians, meaning half of untreated patients die sooner and half live longer. For some, the timeline is measured in weeks; for others, the disease moves more slowly.

A study using the U.S. SEER-Medicare database looked specifically at older patients (average age around 80) who received neither chemotherapy nor supportive care. Nearly 80 percent died within 60 days of diagnosis, and more than 95 percent were dead within 180 days.³ Only about 2 percent survived past 12 months. Those numbers reflect a very elderly, often medically fragile population, so they represent a floor estimate for untreated survival rather than a universal one. Younger patients who refuse treatment might survive somewhat longer on average, though the trajectory still tends to be measured in months, not years.

Why AML Progresses So Quickly Without Treatment

AML is a cancer of immature white blood cells, called blasts, that multiply rapidly in the bone marrow. These blasts crowd out the normal cells that produce red blood cells, healthy white blood cells, and platelets. Laboratory research has shown that leukemic cells actively suppress normal blood cell production, both by physically taking up space and by releasing substances that damage the bone marrow’s support structures and the stem cells that would otherwise keep making healthy blood.⁴ The result is a cascading failure of the blood system.

Without treatment, this process runs unchecked. Red blood cell counts drop, causing severe anemia and exhaustion. Platelet counts plummet, making the person vulnerable to bleeding that ranges from bruising and nosebleeds to life-threatening hemorrhages in the gut or brain. Functional white blood cells disappear, leaving the immune system unable to fight off infections. In untreated patients, the immediate cause of death is usually overwhelming infection or uncontrolled bleeding, rather than organ invasion by the leukemia itself.

One particularly dangerous complication is a blood-clotting disorder called disseminated intravascular coagulation, or DIC. In a study of AML patients, DIC with active bleeding at diagnosis was found in about half of those with the APL subtype and about 13 percent of those with other AML subtypes. Fatal hemorrhage accounted for roughly 40 percent of all early deaths during treatment induction.⁵ Without any treatment at all, these clotting abnormalities go unmanaged, and the bleeding risk is even higher.

What Determines Whether Someone Survives Weeks or Months

Plenty of untreated AML patients die within weeks, while a handful survive past a year. Several factors shape where on that spectrum a person falls.

Age and frailty: Older patients tend to have worse outcomes even with treatment, and the same holds without it. In the SEER-Medicare analysis, the average age of untreated patients was about 80, and coexisting conditions like chronic kidney disease, heart disease, and depression were all linked to shorter survival.³
Blast percentage and burden: How aggressively the leukemia has already overtaken the marrow at diagnosis matters. Higher blast percentages and higher white blood cell counts both signal faster progression. One study found that blast percentages of 90 percent or more were independently associated with worse short-term survival in AML patients with leukostasis.⁶
Genetic and molecular profile: AML is not a single disease but a collection of genetically distinct subtypes. Some subtypes are inherently more aggressive. AML that develops after a prior blood disorder like myelodysplastic syndrome (secondary AML) carries a worse prognosis than AML that arises on its own (de novo AML). A large survival analysis found that secondary AML patients had an 8 percent higher risk of dying, and the gap was especially wide in younger patients whose AML followed myelodysplastic syndrome.⁷
Organ function: Kidney function at diagnosis is a strong predictor. The leukostasis study found that creatinine levels above 1.4 mg/dL were independently associated with worse 28-day survival.⁶

These factors interact. An 85-year-old with secondary AML, chronic kidney disease, and a very high blast count at diagnosis might survive only days to weeks without intervention. A 70-year-old with de novo AML, low blast counts, and relatively preserved organ function might live several months and potentially longer.

The Outliers Who Survive Much Longer

The two-month median obscures a genuinely interesting subgroup: patients whose untreated AML follows an unusually slow, or “indolent,” course. A study from the PETHEMA registry looked at over 2,500 patients aged 60 or older who received only best supportive care, which included transfusions, infection management, and sometimes mild oral medications like hydroxyurea but not standard chemotherapy. About 7.6 percent of these patients survived at least nine months and qualified as having indolent AML. Their median survival was nearly 15 months, a dramatic difference from the non-indolent group, whose median was less than one month.⁸

What makes indolent AML different is not yet fully understood, but it likely relates to the specific genetic mutations driving the disease. Some mutations cause a slower accumulation of blasts or leave more room for normal blood production to continue at a low level. These patients still have AML, and the disease typically does progress, but on a timeline measured in a year or more rather than weeks. Recognizing indolent AML at diagnosis remains difficult because the standard blood and marrow tests do not clearly distinguish it from the aggressive majority. In practice, it often becomes apparent only in retrospect, when a patient who was expected to decline rapidly is still alive months later.

Spontaneous Remission

Perhaps the most striking outlier phenomenon in untreated AML is spontaneous remission, where the leukemia temporarily retreats on its own. This is genuinely rare, but it has been documented enough times to rule out fluke misdiagnosis. A review of the medical literature found 46 documented cases. In the overwhelming majority, about 91 percent, the patient had a fever before remission, and about 71 percent had a confirmed infection. The leading theory is that severe infection triggers a massive immune response that happens to also attack the leukemic cells.⁹

A case report described an 80-year-old woman whose AML went into remission three separate times, each time following a different infection. During each episode, her leukemic cells disappeared from the bloodstream and her blood counts improved without chemotherapy. The effects lasted months each time, and she survived more than two years beyond the median survival expected for someone her age with end-stage AML.¹⁰ These remissions are almost always temporary. The leukemia eventually returns. But they demonstrate that the immune system can, in rare circumstances, exert meaningful control over AML, which is one reason researchers are interested in immunotherapy approaches for the disease.

Why Nearly a Third of Older Patients Go Untreated

A point that surprises many people: a substantial number of AML patients never receive chemotherapy at all. In the SEER-Medicare analysis, 31 percent of older AML patients received neither standard treatment nor supportive care.³ The reasons are layered and often misunderstood. It is not always a matter of patients giving up.

In national database analyses, about 11 percent of untreated cases were attributed to patient or family refusal. A study from India found that more than half of patients who refused active treatment cited reasons like lack of family support, distance from treatment centers, and financial constraints rather than a belief that treatment would not work.¹¹ In wealthier countries, the decision often involves a calculation about quality of remaining life. Intensive chemotherapy for AML means weeks in the hospital, severe infection risk, nausea, mouth sores, and fatigue. For an 82-year-old with multiple health problems, the chance of achieving remission may be low while the chance of dying from treatment complications is very real.

Research into patient preferences has revealed two distinct decision-making patterns: one group prioritizes avoiding the short-term side effects of treatment, while the other prioritizes achieving complete remission. Women and patients over 60 were more likely to be in the side-effect-avoidant group. Surveys also revealed a troubling gap between what doctors think they communicated and what patients remember hearing. About 21 percent of surveyed patients said their doctor discussed only supportive care, and 28 percent felt the decision-making process did not match their preferences.¹¹ This suggests that some patients end up without treatment partly because the conversation about options did not happen the way it should have.

What “Supportive Care Only” Actually Looks Like

Choosing not to pursue chemotherapy does not mean choosing nothing. Best supportive care for AML typically includes blood and platelet transfusions to manage anemia and bleeding risk, antibiotics and antifungal medications when infections arise, and sometimes oral drugs like hydroxyurea to temporarily slow the rise in white blood cell counts. The goal shifts from trying to eliminate the leukemia to managing symptoms and preserving quality of life for as long as possible.

For context, a single-center study of 355 consecutive older AML patients found that those on best supportive care had substantially shorter survival than those receiving either intensive chemotherapy (median about 15 months) or hypomethylating agents (median about 11 months).¹² Newer, less toxic drugs like hypomethylating agents, sometimes combined with targeted therapies, have expanded options for patients who cannot tolerate intensive chemotherapy. These are not supportive care in the traditional sense; they are active treatment meant to control the disease, and they represent a middle ground between full-intensity chemotherapy and comfort care alone. For some patients who might have been offered only supportive care a decade ago, these regimens offer meaningfully longer survival with more manageable side effects.¹³

The Physical Experience of Untreated AML

Understanding how long someone can survive without treatment is only half of what most people are really asking. The other half is what that time looks like. Qualitative research with leukemia patients has identified several recurring challenges: overwhelming fatigue, frequent fevers, feelings of helplessness, uncertainty about what comes next, activity restriction severe enough that daily life becomes very small, and heavy stress on caregivers.¹⁴ These burdens exist whether or not a patient is receiving chemotherapy, but in untreated patients they tend to escalate steadily rather than cycling through treatment and recovery phases.

The typical trajectory for someone with untreated AML involves a gradual worsening of fatigue and shortness of breath as anemia deepens, increasingly frequent infections that become harder to control, and eventually either a catastrophic bleed or an infection the body simply cannot fight off. Many patients spend a significant portion of their remaining time in the hospital despite not receiving chemotherapy, because the complications of the disease itself require medical attention. Studies of end-of-life care patterns in AML have noted a high rate of hospitalization and intensive care unit use even among patients nearing death, and a persistent underuse of palliative and hospice services.¹⁵ This gap matters: early palliative care involvement does not hasten death but can substantially improve symptom control and emotional support during a very difficult period.

When AML Subtype Changes the Picture

Not all AML behaves the same way without treatment, and the specific subtype can shift the timeline substantially. Acute promyelocytic leukemia (APL, sometimes called AML-M3) is a striking example. Untreated, APL is among the most dangerous forms because of its strong association with DIC and catastrophic bleeding. About half of APL patients have bleeding complications at the time they are diagnosed.⁵ Without treatment, the bleeding risk makes survival extremely short, sometimes days. The irony is that with appropriate treatment, APL is the most curable form of AML, with cure rates above 90 percent. Of any AML subtype, the gap between treated and untreated outcomes is widest in APL.

On the other end of the spectrum, secondary AML that arises after a prior blood disorder generally carries a worse prognosis than de novo AML, both with and without treatment. A large analysis found the survival gap between secondary and de novo AML widened over the study period from about 7 percent to about 14 percent, likely because improvements in treatment benefited de novo AML patients more than secondary AML patients.⁷ For untreated patients, this distinction still matters: the biology of secondary AML tends to be more resistant and unpredictable, often making the disease trajectory harder to forecast.

AML with certain favorable genetic mutations may also behave differently untreated, though data specifically on untreated patients with favorable-risk genetics are thin. Most patients with favorable-risk AML are treated aggressively precisely because their chances of cure are high, so the untreated natural history of these subtypes is largely unknown from modern data. The general principle is that the biological aggressiveness encoded in the leukemia’s DNA affects how fast it would progress regardless of whether treatment is given.

Making the Decision in Practice

For patients and families facing this question in real time, the numbers provide a framework but not an answer. A two-month median survival without treatment means roughly half of patients live longer, and a meaningful subset survives six months or more, especially with good supportive care. But the quality of those months depends heavily on the intensity of symptom management, access to transfusions, and the availability of palliative support.

The decision is also not always binary. The treatment landscape has shifted in the past decade. Low-intensity options that did not exist fifteen years ago now allow some older or frailer patients to receive active disease-directed therapy without the full toll of intensive chemotherapy. In cases where AML evolves from a myeloproliferative or myelodysplastic neoplasm, hypomethylating agent-based regimens have shown comparable survival to intensive chemotherapy in older adults.¹³ A patient who would have been told “chemotherapy or nothing” in 2010 may now have a third option that extends survival without requiring weeks in the hospital. The honest conversation about “how long without treatment” should also include what the less-intensive treatment options are, because for many patients, those therapies land in between the extremes of doing nothing and undergoing aggressive induction.